Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Japan’s Ono buys US oncology firm; strong growth but supply issues for Lilly; Novo and Lilly make their money work; BMS cuts jobs, costs; and Big Pharma’s support for bioventures.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 3 May 2024, including: Japan’s Ono Pharmaceutical Company, Ltd. buys US oncology firm; strong growth but supply issues for Eli Lilly and Company; Novo Nordisk A/S and Lilly make their money work; Bristol Myers Squibb Company cuts jobs, costs; and big pharma’s support for bioventures.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Ono Buys Deciphera, Gaining A Commercial Cancer Drug And Infrastructure" - Scrip, 29 Apr, 2024.)
(Also see "Lilly Mounjaro, Zepbound Supply Issues Persist Amid Strong Growth" - Scrip, 30 Apr, 2024.)
(Also see "Analysis: Novo And Lilly Make Their Money Work" - Scrip, 26 Apr, 2024.)
(Also see "BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth" - Scrip, 25 Apr, 2024.)
(Also see "Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs" - Scrip, 1 May, 2024.)